KemPharm IncNASDAQ:KMPH
- LAST PRICE5.4700
- TODAY'S CHANGE (%)0.0100 (0.1832%)
- Bid / Lots5.4200/ 1
- Ask / Lots5.5500/ 6
- Open / Previous Close5.4400 / 5.4600
- Day Range
- 52 Week Range
- Volume114,519
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KMPH |
|---|---|---|
| 09:32 ET | 150 | 5.44 |
| 09:39 ET | 1571 | 5.4 |
| 09:44 ET | 300 | 5.3832 |
| 09:46 ET | 1100 | 5.38 |
| 10:02 ET | 300 | 5.42 |
| 10:04 ET | 500 | 5.41 |
| 10:06 ET | 1162 | 5.45 |
| 10:08 ET | 800 | 5.4583 |
| 10:09 ET | 796 | 5.4301 |
| 10:11 ET | 300 | 5.46 |
| 10:15 ET | 200 | 5.465 |
| 10:18 ET | 100 | 5.465 |
| 10:22 ET | 100 | 5.465 |
| 10:24 ET | 100 | 5.45 |
| 10:26 ET | 100 | 5.46 |
| 10:40 ET | 100 | 5.4475 |
| 10:42 ET | 300 | 5.4439 |
| 10:44 ET | 500 | 5.44 |
| 10:45 ET | 1519 | 5.41 |
| 10:47 ET | 7425 | 5.395 |
| 10:51 ET | 300 | 5.39 |
| 10:56 ET | 100 | 5.38 |
| 10:58 ET | 1400 | 5.38 |
| 11:02 ET | 300 | 5.37 |
| 11:03 ET | 2720 | 5.39 |
| 11:05 ET | 100 | 5.38 |
| 11:07 ET | 200 | 5.38 |
| 11:12 ET | 100 | 5.38 |
| 11:14 ET | 257 | 5.3875 |
| 11:16 ET | 2376 | 5.39 |
| 11:27 ET | 100 | 5.41 |
| 11:30 ET | 600 | 5.42 |
| 11:34 ET | 200 | 5.42 |
| 11:41 ET | 119 | 5.43 |
| 11:45 ET | 400 | 5.42 |
| 11:48 ET | 200 | 5.4293 |
| 11:50 ET | 100 | 5.4201 |
| 11:52 ET | 300 | 5.43 |
| 11:54 ET | 300 | 5.43 |
| 11:57 ET | 343 | 5.42 |
| 11:59 ET | 248 | 5.42 |
| 12:03 ET | 399 | 5.41 |
| 12:08 ET | 100 | 5.41 |
| 12:10 ET | 200 | 5.41 |
| 12:19 ET | 200 | 5.4021 |
| 12:21 ET | 100 | 5.405 |
| 12:24 ET | 800 | 5.4 |
| 12:26 ET | 200 | 5.39 |
| 12:28 ET | 500 | 5.37 |
| 12:30 ET | 300 | 5.37 |
| 12:32 ET | 300 | 5.37 |
| 12:33 ET | 550 | 5.37 |
| 12:35 ET | 100 | 5.37 |
| 12:37 ET | 200 | 5.37 |
| 12:39 ET | 1369 | 5.38 |
| 12:42 ET | 200 | 5.38 |
| 12:44 ET | 300 | 5.37 |
| 12:46 ET | 1495 | 5.35 |
| 12:48 ET | 1016 | 5.35 |
| 12:50 ET | 400 | 5.33 |
| 12:51 ET | 100 | 5.36 |
| 12:53 ET | 300 | 5.35 |
| 12:55 ET | 273 | 5.35 |
| 12:57 ET | 300 | 5.34 |
| 01:00 ET | 200 | 5.34 |
| 01:02 ET | 200 | 5.345 |
| 01:04 ET | 200 | 5.34 |
| 01:06 ET | 300 | 5.34 |
| 01:08 ET | 600 | 5.35 |
| 01:11 ET | 300 | 5.34 |
| 01:13 ET | 100 | 5.349 |
| 01:18 ET | 625 | 5.34 |
| 01:20 ET | 200 | 5.33 |
| 01:22 ET | 350 | 5.34 |
| 01:24 ET | 100 | 5.34 |
| 01:26 ET | 200 | 5.34 |
| 01:27 ET | 200 | 5.34 |
| 01:29 ET | 2119 | 5.34 |
| 01:36 ET | 200 | 5.34 |
| 01:54 ET | 100 | 5.35 |
| 02:00 ET | 100 | 5.36 |
| 02:02 ET | 543 | 5.34 |
| 02:03 ET | 100 | 5.355 |
| 02:07 ET | 2100 | 5.37 |
| 02:09 ET | 100 | 5.3964 |
| 02:12 ET | 1324 | 5.41 |
| 02:16 ET | 200 | 5.42 |
| 02:18 ET | 200 | 5.41 |
| 02:30 ET | 500 | 5.42 |
| 02:32 ET | 1685 | 5.42 |
| 02:34 ET | 100 | 5.41 |
| 02:36 ET | 10983 | 5.37 |
| 02:41 ET | 2000 | 5.408 |
| 02:43 ET | 350 | 5.42 |
| 02:45 ET | 100 | 5.4292 |
| 02:48 ET | 400 | 5.44 |
| 02:50 ET | 230 | 5.44 |
| 02:52 ET | 1600 | 5.445 |
| 02:54 ET | 700 | 5.44 |
| 02:56 ET | 500 | 5.43 |
| 02:59 ET | 600 | 5.435 |
| 03:01 ET | 400 | 5.44 |
| 03:03 ET | 846 | 5.45 |
| 03:06 ET | 1110 | 5.46 |
| 03:08 ET | 810 | 5.4897 |
| 03:10 ET | 300 | 5.4863 |
| 03:12 ET | 100 | 5.48 |
| 03:14 ET | 200 | 5.47 |
| 03:15 ET | 692 | 5.46 |
| 03:19 ET | 100 | 5.45 |
| 03:21 ET | 236 | 5.46 |
| 03:26 ET | 200 | 5.451 |
| 03:30 ET | 100 | 5.45 |
| 03:32 ET | 400 | 5.45 |
| 03:33 ET | 200 | 5.45 |
| 03:35 ET | 300 | 5.47 |
| 03:37 ET | 300 | 5.48 |
| 03:42 ET | 100 | 5.48 |
| 03:46 ET | 100 | 5.49 |
| 03:48 ET | 700 | 5.48 |
| 03:50 ET | 500 | 5.47 |
| 03:51 ET | 900 | 5.45 |
| 03:53 ET | 1000 | 5.45 |
| 03:55 ET | 800 | 5.455 |
| 03:57 ET | 1147 | 5.45 |
| 04:00 ET | 1334 | 5.47 |
Yesterday
KemPharm Enhances Senior Management Team, from 7:30AM ET on Tuesday Jan 31, 2023 by GlobeNewswire
7:30AM ET on Tuesday Jan 31, 2023 by GlobeNewswire
Jan 25, 2023
BRIEF-KemPharm's Cash, Cash Equivalents, Long-Term Investments In 2022$102.9 Mln, from 6:20AM ET on Wednesday Jan 25, 2023 by Thomson Reuters
6:20AM ET on Wednesday Jan 25, 2023 by Thomson Reuters
Jan 24, 2023
KemPharm Issues Letter to Shareholders, from 7:30AM ET on Tuesday Jan 24, 2023 by GlobeNewswire
7:30AM ET on Tuesday Jan 24, 2023 by GlobeNewswire
Jan 18, 2023
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy, from 7:30AM ET on Wednesday Jan 18, 2023 by GlobeNewswire
7:30AM ET on Wednesday Jan 18, 2023 by GlobeNewswire
Jan 11, 2023
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer, from 7:30AM ET on Wednesday Jan 11, 2023 by GlobeNewswire
7:30AM ET on Wednesday Jan 11, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
KemPharm Inc | 188.4M | -5.4x | --- |
Shattuck Labs Inc | 176.8M | -2.5x | --- |
Y-mAbs Therapeutics Inc | 196.1M | -1.5x | --- |
Ikena Oncology Inc | 154.5M | -2.9x | --- |
Sol Gel Technologies Ltd | 131.5M | 30.9x | --- |
Sesen Bio Inc | 125.4M | -34.9x | --- |
Company Information
KemPharm, Inc. (KemPharm) is a specialty pharmaceutical company focused on the discovery and development of treatments for central nervous system (CNS), and rare disease indications, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder (SUD) and idiopathic hypersomnia (IH). It is focused on the discovery and development of prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) technology. KemPharm utilizes its LAT technology to generate prodrug versions of Food and Drug Administration (FDA) approved drugs. KemPharm's lead clinical development product candidate for the treatment of IH and narcolepsy, KP1077, is based on serdexmethylphenidate (SDX), its prodrug of d-methlyphenidate (d-MPH). Its prodrug product candidate for the treatment of SUD is KP879. In addition, KemPharm has received FDA approval for AZSTARYS, a once-daily treatment for ADHD in patents age six years and older.
Contact Information
- Headquarters
- 1180 Celebration Blvd Ste 103CELEBRATION, FL, United States 34747-4950
- Phone
- 321-939-3416
- Fax
- 319-665-2577
Executives
- Independent Chairman of the Board
- Matthew Plooster
- Chief Executive Officer, Director
- Richard Pascoe
- Chief Financial Officer, Treasurer, Secretary
- R. LaDuane Clifton
- Executive Vice President - Research and Development
- Sven Guenther
- Vice President, Corporate Controller
- Timothy Sangiovanni
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $188.4M |
|---|---|
Revenue (TTM) | $10.7M |
Shares Outstanding | 34.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.16 |
EPS | $-1.02 |
Book Value | $3.63 |
P/E Ratio | -5.4x |
Price/Sales (TTM) | 17.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -336.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
